



07-23-04

CASE N-30895B

AF 761/\$
EPW

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 540156818 US

Express Mail Label Number

July 22, 2004

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1761

MICHELS ET AL.

APPLICATION NO: 10/092,637

FILED: MARCH 7, 2002

FOR: COMPOSITION AND METHOD FOR PROLONGING THE USEFUL
LIFE OF ENTERAL FEEDING TUBES

Amendment - IDS
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of a supplemental Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7877
Date:

July 22, 2004


John W. Kung
Attorney for Applicants
Reg. No. 44,199

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 540156818 US
Express Mail Label Number

JULY 22, 2004
Date of Deposit



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1761

MICHELS ET AL.

APPLICATION NO: 10/092,637

FILED: MARCH 7, 2002

FOR: COMPOSITION AND METHOD FOR PROLONGING THE USEFUL
LIFE OF ENTERAL FEEDING TUBES

MS: Amendment - IDS

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed April 19, 2002. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.

07/26/2004 WABDELRI 00000015 190134 10092637
01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7877


John W. Kung
Attorney for Applicants
Reg. No. 44,199

Date: 7/22/2004

ATTY. DOCKET NO.

N-30895B

APPLICATION NO.

10/092,637

APPLICANT

MICHELS ET AL.

FILING DATE

MARCH 7, 2002

Group
1761

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	EP 0 433 516	6/26/91	Europe			
	AB	GB 1298 154	3/2/70	Great Britain			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.